CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PTPN14 (ImmuneEditome ID:5784)

1. Gene summary of enriched editing regions for PTPN14

check button Gene summary
Gene informationGene symbol

PTPN14

Gene ID

5784

GeneSynonymsCATLPH|PEZ|PTP36|PTPD2
GeneCytomap

1q32.3-q41

GeneTypeprotein-coding
GeneDescriptiontyrosine-protein phosphatase non-receptor type 14|cytoskeletal-associated protein tyrosine phosphatase|protein-tyrosine phosphatase pez
GeneModificationdate20230517
UniprotIDQ15678;E2J9M0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:214528690-214530592:-ENST00000491277.1ENSG00000152104.10PTPN14ncRNA_exonicAluSz6,AluJr,AluJb,AluSzchr1:214528690-214530592:-.alignment


Top

2. Tumor-specific enriched editing regions for PTPN14


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000152104.10,PTPN14PRADEAG8.5350e-03image
ENSG00000152104.10,PTPN14UCECEAG6.2183e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000152104.10,PTPN14TGCTCliEAG1.3769e-021.0806e-02-0.2909image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000152104.10,PTPN14HNSCEAG4.0528e-021.5181e-021.3253e-01image
ENSG00000152104.10,PTPN14LIHCEAG3.0087e-024.6803e-023.6511e-02image

Top

3. Enriched editing regions and immune related genes for PTPN14


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for PTPN14


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000152104.10,PTPN14
KIRCEAGMEXENSG00000096384.15chr644247086:44247195:44248629:44248776:44252162:44252267:44253044:442533780.43552.4870e-157.5749e-190.4346imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CAPRIN1;CBX7;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL1;MBNL2;MOV10;MSI1;MSI2;NCBP3;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;RBM6;RC3H1;RTCB;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184HSP90AB1T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000152104.10,PTPN14
KIRCEAGMEXENSG00000174718.7chr1231970188:31970356:31980877:31986007:31987244:31987322:31992377:319929410.42164.0157e-148.4389e-170.4115imageNADAR;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RC3H1;RTCB;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000152104.10,PTPN14
KIRCEAGMEXENSG00000141736.9chr1739723911:39724010:39724725:39724911:39726561:39726659:39726814:397270030.40221.5040e-124.9525e-170.4138imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RTCB;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184ERBB2T_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000152104.10,PTPN14
KIRCEAGIRENSG00000108799.8chr1742717975:42718067:42718453:42718617-0.35141.5009e-093.7927e-16-0.4100imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP7;LIN28;LIN28B;MBNL2;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000152104.10,PTPN14
KIRCEAGIRENSG00000115486.7chr285558439:85558605:85558916:85559075-0.35351.5548e-091.2207e-16-0.4106imageNADAR;AIFM1;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL1;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184GGCXT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000152104.10,PTPN14
KIRCEAGMEXENSG00000159063.8chr1178104355:78104453:78106806:78106946:78114265:78114392:78119181:78119249-0.39085.7047e-122.7171e-17-0.4170imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7BNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000152104.10,PTPN14
PAADEAGMEXENSG00000134759.9chr1836159957:36160015:36160931:36161004:36167155:36167222:36170062:361701960.41941.7605e-031.8278e-070.4030imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;RBM6;RC3H1;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184ELP2T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000152104.10,PTPN14
PAADEAGMEXENSG00000116062.10chr247790926:47791123:47795893:47796073:47800665:47801155:47803419:478036850.41901.7810e-039.2654e-080.4130imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CAPRIN1;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NCBP3;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;RC3H1;RTCB;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184MSH6T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000152104.10,PTPN14
PAADEAGMEXENSG00000134759.9chr1836159959:36160015:36160931:36161004:36167152:36167222:36170062:361701960.41891.8053e-031.8952e-070.4025imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM47;RBM5;RBM6;RC3H1;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184ELP2T_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
ENSG00000152104.10,PTPN14
TGCTEAGIRENSG00000178980.10chr1947778571:47778814:47779955:47780068-0.22733.6259e-022.0083e-05-0.4050imageNADAR;AIFM1;BCCIP;BUD13;CAPRIN1;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;LARP4B;LIN28;LIN28A;LIN28B;MBNL1;MBNL2;MOV10;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RC3H1;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;YTHDF1;ZNF184NAMacrophages_M0

More results



Top

5. Enriched editing regions and immune infiltration for PTPN14


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000152104.10,PTPN14BLCAEAGMast_cells_resting3.5188e-03-0.1650image
ENSG00000152104.10,PTPN14BRCAEAGT_cells_CD4_memory_resting1.2272e-040.1202image
ENSG00000152104.10,PTPN14CHOLEAGT_cells_regulatory_(Tregs)9.1979e-030.4601image
ENSG00000152104.10,PTPN14COADEAGDendritic_cells_activated4.9861e-050.3545image
chr1:214528690-214530592:-ESCAEERNK_cells_activated3.2304e-020.2701image
ENSG00000152104.10,PTPN14ESCAEAGMacrophages_M12.4362e-02-0.1774image
ENSG00000152104.10,PTPN14HNSCEAGT_cells_CD4_naive4.8863e-03-0.1295image
ENSG00000152104.10,PTPN14KIRCEAGMacrophages_M21.5223e-050.2205image
ENSG00000152104.10,PTPN14KIRPEAGMast_cells_resting2.2066e-020.1484image
ENSG00000152104.10,PTPN14LAMLEAGMonocytes5.7791e-030.4188image
ENSG00000152104.10,PTPN14LGGEAGNK_cells_activated1.4865e-02-0.1387image
ENSG00000152104.10,PTPN14LIHCEAGMacrophages_M12.4819e-030.2538image
ENSG00000152104.10,PTPN14LUADEAGT_cells_regulatory_(Tregs)3.1156e-03-0.1421image
ENSG00000152104.10,PTPN14LUSCEAGMonocytes1.3199e-02-0.1138image
ENSG00000152104.10,PTPN14MESOEAGDendritic_cells_activated9.7470e-030.2874image
chr1:214528690-214530592:-OVEERT_cells_follicular_helper2.7449e-02-0.2715image
ENSG00000152104.10,PTPN14OVEAGT_cells_CD81.4809e-020.1427image
ENSG00000152104.10,PTPN14PAADEAGMacrophages_M12.6121e-030.2394image
ENSG00000152104.10,PTPN14PCPGEAGPlasma_cells2.4648e-02-0.2665image
ENSG00000152104.10,PTPN14PRADEAGDendritic_cells_resting5.3573e-050.1918image
ENSG00000152104.10,PTPN14READEAGNK_cells_resting1.5579e-020.3473image
ENSG00000152104.10,PTPN14SKCMEAGT_cells_regulatory_(Tregs)2.6755e-03-0.1415image
chr1:214528690-214530592:-STADEERPlasma_cells2.9997e-040.4061image
ENSG00000152104.10,PTPN14STADEAGT_cells_CD4_memory_activated1.8109e-030.1630image
ENSG00000152104.10,PTPN14TGCTEAGT_cells_CD88.1630e-040.2837image
ENSG00000152104.10,PTPN14THCAEAGPlasma_cells4.1927e-04-0.1594image
ENSG00000152104.10,PTPN14THYMEAGT_cells_CD88.9036e-03-0.2773image
ENSG00000152104.10,PTPN14UCSEAGT_cells_gamma_delta8.6745e-030.3827image
ENSG00000152104.10,PTPN14UVMEAGMast_cells_activated6.0484e-040.4370image


Top

6. Enriched editing regions and immune gene sets for PTPN14


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
ENSG00000152104.10,PTPN14STADEAG4.9821e-07image1.5235e-02-0.1271image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000152104.10,PTPN14ACCGSVA_HALLMARK_GLYCOLYSISEAG2.4405e-03-0.4455image
ENSG00000152104.10,PTPN14BLCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.0747e-03-0.1673image
ENSG00000152104.10,PTPN14BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4500e-070.1641image
ENSG00000152104.10,PTPN14CESCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.2903e-030.1820image
ENSG00000152104.10,PTPN14CHOLGSVA_HALLMARK_GLYCOLYSISEAG2.1453e-02-0.4115image
ENSG00000152104.10,PTPN14COADGSVA_HALLMARK_ADIPOGENESISEAG2.8815e-06-0.4045image
chr1:214528690-214530592:-ESCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.2273e-020.3138image
ENSG00000152104.10,PTPN14ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.7105e-02-0.1644image
ENSG00000152104.10,PTPN14GBMGSVA_HALLMARK_UV_RESPONSE_DNEAG2.1836e-040.3486image
ENSG00000152104.10,PTPN14HNSCGSVA_HALLMARK_UV_RESPONSE_DNEAG5.8485e-030.1268image
ENSG00000152104.10,PTPN14KIRCGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.6392e-070.2558image
ENSG00000152104.10,PTPN14KIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG6.0347e-04-0.2208image
ENSG00000152104.10,PTPN14LAMLGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG2.0182e-020.3573image
ENSG00000152104.10,PTPN14LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG2.6504e-050.2370image
ENSG00000152104.10,PTPN14LIHCGSVA_HALLMARK_ADIPOGENESISEAG9.4298e-040.2765image
ENSG00000152104.10,PTPN14LUADGSVA_HALLMARK_G2M_CHECKPOINTEAG1.0255e-030.1576image
ENSG00000152104.10,PTPN14LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.7652e-030.1372image
ENSG00000152104.10,PTPN14MESOGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.6236e-03-0.3069image
chr1:214528690-214530592:-OVGSVA_HALLMARK_MITOTIC_SPINDLEEER2.5712e-02-0.2745image
ENSG00000152104.10,PTPN14OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.6753e-060.2712image
ENSG00000152104.10,PTPN14PAADGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.4140e-050.3174image
ENSG00000152104.10,PTPN14PCPGGSVA_HALLMARK_MYOGENESISEAG8.4826e-04-0.3873image
ENSG00000152104.10,PTPN14PRADGSVA_HALLMARK_DNA_REPAIREAG3.9286e-11-0.3088image
ENSG00000152104.10,PTPN14SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.5466e-020.1370image
ENSG00000152104.10,PTPN14SKCMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.0108e-03-0.1548image
ENSG00000152104.10,PTPN14STADGSVA_HALLMARK_MTORC1_SIGNALINGEAG7.3009e-040.1763image
ENSG00000152104.10,PTPN14TGCTGSVA_HALLMARK_HYPOXIAEAG7.9096e-07-0.4085image
ENSG00000152104.10,PTPN14THCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.0873e-130.3226image
ENSG00000152104.10,PTPN14THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG3.4578e-020.2256image
ENSG00000152104.10,PTPN14UCECGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.3896e-02-0.1888image
ENSG00000152104.10,PTPN14UCSGSVA_HALLMARK_ANGIOGENESISEAG2.5291e-02-0.3296image


Top

7. Enriched editing regions and drugs for PTPN14


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000152104.10,PTPN14ACCJW.7.52.1EAG3.3339e-020.3215image
ENSG00000152104.10,PTPN14BLCABMS.754807EAG5.1155e-040.1959image
ENSG00000152104.10,PTPN14BRCABMS.536924EAG2.5649e-080.1739image
ENSG00000152104.10,PTPN14CESCCGP.082996EAG8.5664e-04-0.2059image
ENSG00000152104.10,PTPN14CHOLBortezomibEAG4.1139e-030.5008image
ENSG00000152104.10,PTPN14COADAZ628EAG1.2094e-050.3804image
ENSG00000152104.10,PTPN14ESCAFTI.277EAG4.8682e-030.2209image
chr1:214528690-214530592:-ESCAEmbelinEER4.7851e-030.3511image
ENSG00000152104.10,PTPN14GBMAZD6482EAG4.2042e-04-0.3335image
ENSG00000152104.10,PTPN14HNSCBortezomibEAG3.7186e-030.1334image
ENSG00000152104.10,PTPN14KICHABT.263EAG4.4421e-02-0.2978image
ENSG00000152104.10,PTPN14KIRCBMS.536924EAG3.0535e-160.4051image
ENSG00000152104.10,PTPN14KIRPBosutinibEAG4.6008e-05-0.2609image
ENSG00000152104.10,PTPN14LAMLCytarabineEAG1.5240e-020.3721image
ENSG00000152104.10,PTPN14LGGBMS.536924EAG1.8330e-030.1772image
ENSG00000152104.10,PTPN14LIHCDocetaxelEAG1.2090e-02-0.2116image
ENSG00000152104.10,PTPN14LUADBexaroteneEAG1.9652e-030.1487image
ENSG00000152104.10,PTPN14LUSCEmbelinEAG4.9116e-03-0.1290image
ENSG00000152104.10,PTPN14MESOBAY.61.3606EAG1.4282e-03-0.3506image
chr1:214528690-214530592:-OVBI.2536EER4.4832e-020.2478image
ENSG00000152104.10,PTPN14OVBexaroteneEAG7.5903e-090.3305image
ENSG00000152104.10,PTPN14PAADElesclomolEAG2.0296e-040.2932image
ENSG00000152104.10,PTPN14PCPGElesclomolEAG1.9089e-040.4288image
ENSG00000152104.10,PTPN14PRADBMS.536924EAG8.5593e-070.2334image
ENSG00000152104.10,PTPN14READCEP.701EAG9.6159e-03-0.3701image
ENSG00000152104.10,PTPN14SARCAG.014699EAG5.5394e-050.2593image
ENSG00000152104.10,PTPN14SKCMCEP.701EAG2.0800e-030.1451image
ENSG00000152104.10,PTPN14STADAP.24534EAG4.0235e-050.2135image
chr1:214528690-214530592:-STADGDC.0449EER1.3899e-02-0.2830image
ENSG00000152104.10,PTPN14TGCTIPA.3EAG2.3583e-06-0.3920image
ENSG00000152104.10,PTPN14THCACEP.701EAG5.0960e-120.3066image
ENSG00000152104.10,PTPN14THYMBIBW2992EAG2.9577e-03-0.3133image
ENSG00000152104.10,PTPN14UCECBosutinibEAG7.6844e-03-0.2221image
ENSG00000152104.10,PTPN14UCSBexaroteneEAG1.7203e-020.3497image
ENSG00000152104.10,PTPN14UVMAG.014699EAG2.6295e-02-0.2917image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType